AbCellera Biologics Inc. (NASDAQ: ABCL) announced the appointment of Dr. Victor Sandor as an independent director to its board of directors.

Dr. Sandor previously served as Chief Medical Officer at Array BioPharma Inc. before its acquisition by Pfizer Inc., where he secured approval of Braftovi and Mektovi. He also held the position of Senior Vice President for Global Clinical Development at Incyte Corporation, contributing to the approval of Jakafi.

His career includes roles as Vice President and Chief Medical Officer for Oncology at Biogen Inc. and positions at AstraZeneca Pharmaceuticals LP, where he contributed to the registration of Arimidex and development of Faslodex.

"Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients in need," said Carl Hansen, founder and CEO of AbCellera.

Dr. Sandor currently serves on the boards of ADC Therapeutics SA, Kymera Therapeutics Inc., and Prelude Therapeutics Incorporated. He previously served on the board of Merus N.V. before its acquisition by Genmab A/S in 2025.

Dr. Sandor received his M.D.C.M. from McGill University and completed a Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.

AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women's health, immunology, and oncology.